[1] Umehara H, Okazaki K, Masaki Y, et al.A novel clinical entity, IgG4-related disease (IgG4RD): general concept and details[J]. Mod Rheumatol, 2012, 22(1): 1-14. [2] Zhou W, Li Y, Yan C, et al.The prevalence of extra-salivary gland complications in immunoglobulin G4-related sialadenitis[J]. Oral Dis, 2022, 28(6):1468-1483. [3] Pu J, Jia M, Shi W, et al.Immunohistochemical analysis of pyroptosis-related protein expression in IgG4-related sialadenitis[J]. J Oral Pathol Med, 2022, 51(4): 388-394. [4] Balint G, Watson Buchanan W, Kean CA, et al.Sjögren's syndrome[J]. Inflammopharmacology, 2024, 32(1): 37-43. [5] 俞光岩, 洪霞, 李巍, 等. IgG4 相关唾液腺炎的临床病理特点及诊断[J]. 北京大学学报(医学版), 2019, 51(1): 1-3. Yu GY, Hong X, Li W, et al.Clinicopathological characteristics and diagnosis of IgG4-related sialadenitis[J]. Journal of Peking University: Health Sciences, 2019, 51(1): 1-3. [6] Liu C, Zhang P, Zhang W.Immunological mechanism of IgG4-related disease[J]. J Transl Autoimmun, 2020, 3: 100047. [7] 李晨曦, 龚忠诚, 郑佞波. 肿瘤源性外泌体对巨噬细胞极化的调控作用的研究进展[J]. 中华微生物学和免疫学杂志, 2023, 43(1): 76-83. Li CX, Gong ZC, Zheng NB.Progress in the regulatory effects of tumor-derived exosomes on macrophage polarization[J]. Chinese Journal of Microbiology and Immunology, 2023, 43(1): 76-83. [8] Cutolo M, Campitiello R, Gotelli E, et al.The role of M1/M2 macrophage polarization in rheumatoid arthritis synovitis[J]. Front Immunol, 2022, 13: 867260. [9] Wang C, Ma C, Gong L, et al.Macrophage polarization and its role in liver disease[J]. Front Immunol, 2021, 12: 803037. [10] Lasch M, Sudan K, Paul C, et al.Isolation of decidual macrophages and hofbauer cells from term placenta-comparison of the expression of CD163 and CD80[J]. Int J Mol Sci, 2022, 23(11): 6113. [11] Cao Y, Li Q, Liu H, et al.Role of Tim-3 in regulating tumorigenesis, inflammation, and antitumor immunity therapy[J]. Cancer Biomark, 2021, 32(2): 237-248. [12] Zhang W, Zhang Y, He Y, et al.Lipopolysaccharide mediates time-dependent macrophage M1/M2 polarization through the Tim-3/Galectin-9 signalling pathway[J]. Exp Cell Res, 2019, 376(2): 124-132. [13] 钱嘉航, 任军, 贾凌云, 等. 自身免疫性疾病与自身抗体概述[J]. 中国免疫学杂志, 2022, 38(17): 2152-2158. Qian JH, Ren J, Jia LY, et al.An overview of autoimmune diseases and autoantibodies[J]. Chinese Journal of Immunology, 2022, 38(17): 2152-2158. [14] 蒲娇, 胡露露, 牛雅琪, 等. 31例IgG4 相关性疾病的临床分析[J]. 口腔医学研究, 2021, 37(2): 173-178. Pu J, Hu LL, Niu QY, et al.Clinical analysis of thirty-one cases of IgG4-related disease[J]. Journal of Oral Science Research, 2021, 37(2): 173-178. [15] 张盼盼, 赵继志, 王木, 等. IgG4 相关性疾病346例临床特征分析[J]. 中华内科杂志, 2017, 56(9): 644-649. Zhang PP, Zhao JZ, Wang M, et al.The clinical characteristics of 346 patients with IgG4-related disease[J]. Chinese Journal of Internal Medicine, 2017, 56(9): 644-649. [16] 夏荣辉, 胡宇华, 钱佳骏, 等. IgG4相关唾液腺炎临床病理特征分析[J]. 中华口腔医学杂志, 2023, 58(8): 815-820. Xia RH, Hu YH, Qian JJ, et al.Analysis of clinicopathological characteristics of IgG4-related sialadenitis[J]. Chinese Journal of Stomatology, 2023, 58(8): 815-820. [17] Fragoulis GE, Zampeli E, Moutsopoulos HM.IgG4-related sialadenitis and Sjögren's syndrome[J]. Oral Dis, 2017, 23(2): 152-156. [18] Zhang YY, Hong X, Wang Z, et al.Diagnostic utility of submandibular and labial salivary gland biopsy in IgG4-related sialadenitis[J]. Clin Rheumatol, 2020, 39(12): 3715-3721. [19] Cheng D, Chai J, Wang H, et al.Hepatic macrophages: key players in the development and progression of liver fibrosis[J]. Liver Int, 2021, 41(10): 2279-2294. [20] Wu N, Xu XF, Xin JQ, et al.The effects of nuclear factor-kappa B in pancreatic stellate cells on inflammation and fibrosis of chronic pancreatitis[J]. J Cell Mol Med, 2021, 25(4): 2213-2227. [21] Tsuboi H, Honda F, Takahashi H, et al.Pathogenesis of IgG4-related disease. comparison with Sjögren's syndrome[J]. Mod Rheumatol, 2020, 30(1): 7-16. [22] Chinju A, Moriyama M, Kakizoe-Ishiguro N, et al.CD163+ M2 macrophages promote fibrosis in IgG4-related disease via Toll-like receptor 7/interleukin-1 receptor-associated kinase 4/NF-κB signaling[J]. Arthritis Rheumatol, 2022, 74(5): 892-901. [23] 罗璇, 彭钰, 费允云. IgG4 相关性疾病复发的危险因素[J]. 中华临床免疫和变态反应杂志, 2019, 13(6): 480-482. Luo X, Peng Y, Fei YY.Risk factors for relapse of IgG4-related diseases[J]. Chinese Journal of Allergy & Clinical Immunology, 2019, 13(6): 480-482. [24] Yunyun F, Yu P, Panpan Z, et al.Efficacy and safety of low dose mycophenolate mofetil treatment for immunoglobulin G4-related disease: a randomized clinical trial[J]. Rheumatology (Oxford), 2019, 58(1): 52-60. [25] Hesketh M, Sahin KB, West ZE, et al.Macrophage phenotypes regulate scar formation and chronic wound healing[J]. Int J Mol Sci, 2017, 18(7): 1545. [26] Kung CC, Dai SP, Chiang H, et al.Temporal expression patterns of distinct cytokines and M1/M2 macrophage polarization regulate rheumatoid arthritis progression[J]. Mol Biol Rep, 2020, 47(5): 3423-3437. [27] Feng Y, Ren J, Gui Y, et al.Wnt/β-catenin-promoted macrophage alternative activation contributes to kidney fibrosis[J]. J Am Soc Nephrol, 2018, 29(1): 182-193. [28] He Y, Gao Y, Zhang Q, et al.IL-4 switches microglia/macrophage M1/M2 polarization and alleviates neurological damage by modulating the JAK1/STAT6 pathway following ICH[J]. Neuroscience, 2020, 437: 161-171. [29] Dhar D, Baglieri J, Kisseleva T, et al.Mechanisms of liver fibrosis and its role in liver cancer[J]. Exp Biol Med (Maywood), 2020, 245(2): 96-108. [30] Moar P, Tandon R.Galectin-9 as a biomarker of disease severity[J]. Cell Immunol, 2021, 361: 104287. [31] 林道泼, 邵晓晓, 胡定元, 等. Tim-3调控巨噬细胞极化在克罗恩病发生发展中的作用[J]. 温州医科大学学报, 2022, 52(12): 947-955. Lin DP, Shao XX, Hu DY, et al.The role of Tim-3 in regulating macrophage polarization in the occurrence and development of Crohn's disease[J]. Journal of Wenzhou Medical University, 2022, 52(12): 947-955. [32] Kang J, Wei ZF, Li MX, et al.Modulatory effect of Tim-3/Galectin-9 axis on T-cell-mediated immunity in pulmonary tuberculosis[J]. J Biosci, 2020, 45: 60. [33] Wang Y, Kuai Q, Gao F, et al.Overexpression of TIM-3 in macrophages aggravates pathogenesis of pulmonary fibrosis in mice[J]. Am J Respir Cell Mol Biol, 2019, 61(6): 727-736. |